The invention relates to the pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yne-3-one-3E-oxime isomer of formula (IA), the pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yne-3-one-3Z-oxime isomer of formula (IB), which are of gestagen activity, as well as the process for the synthesis of the mixture of the above isomers and the pure isomers. The invention also relates to the pharmaceutical compositions - and the process for their synthesis - which contain either the pure isomer of formula (IA) or the pure isomer of formula (IB) as active ingredient as such or in combination with other active ingredients (for example an oestrogen agent) together with pharmaceutical auxiliary materials commonly used in practice.
该发明涉及公式(IA)的纯d-(17α)-13-乙基-17-羟基-18,19-二诺孕烷-4-烯-20-炔-3-酮-3E-
肟异构体,以及公式(IB)的纯d-(17α)-13-乙基-17-羟基-18,19-二诺孕烷-4-烯-20-炔-3-酮-3Z-
肟异构体,它们具有孕激素活性,以及合成上述异构体混合物和纯异构体的方法。该发明还涉及含有公式(IA)的纯异构体或公式(IB)的纯异构体作为活性成分的药物组合物,以及它们的合成方法,这些药物组合物可以单独使用或与其他活性成分(例如
雌激素剂)一起使用,以及通常在实践中使用的
药用辅料。